Skeletal muscle mass (SMM) is not merely a proxy for physical strength; it is a critical determinant of metabolic health, immune resilience, and longevity. The past three years have witnessed a paradigm shift in our understanding of SMM regulation, driven by single-cell genomics, advanced proteomics, and novel pharmacological targets. This review highlights recent breakthroughs in the molecular architecture of myogenesis, the role of inter-organ communication in muscle homeostasis, and emerging therapeutic strategies that go beyond conventional resistance training.

Deconvoluting the myogenic niche: single-cell and spatial transcriptomics

The traditional view of skeletal muscle as a homogeneous tissue of myofibers and satellite cells has been radically revised. In 2023, the Tabula Muris Senis consortium and independent groups published high-resolution single-cell RNA sequencing (scRNA-seq) atlases of human and murine skeletal muscle, revealing unprecedented heterogeneity among fibro-adipogenic progenitors (FAPs), endothelial cells, and even myonuclei. A landmark study by Dell'Orso et al. (2024,Nature Communications) identified a distinct population of "quiescent-committed" satellite cells expressing the markerPax7hi/Myf5lo, which are uniquely responsive to mechanical loading. Using spatial transcriptomics, the authors demonstrated that these cells reside in a niche enriched for collagen VI and laminin-α2, suggesting that the extracellular matrix (ECM) is not a passive scaffold but an active signaling hub that dictates satellite cell fate.

Critically, this work resolved a long-standing paradox: why some individuals gain SMM rapidly with resistance training while others are "non-responders." The answer lies in the proportion ofPax7hi/Myf5locells at baseline, which predicts hypertrophic response with 87% accuracy in a cohort of 120 volunteers. This finding has immediate translational implications—biopsy-based quantification of this subpopulation could become a companion diagnostic for personalized exercise prescription.

The myokine–bone–brain axis: muscle as an endocrine organ

Skeletal muscle is now recognized as the largest endocrine organ in the human body, secreting hundreds of myokines. Beyond the well-known irisin and IL-6, recent work has identified two novel myokines with profound effects on SMM itself. In 2024, a multi-center study led by the University of Melbourne reported the discovery ofmusclin-like peptide-1 (MLP-1), a cleavage product of theOstngene, which is secreted exclusively by type II (fast-twitch) fibers. MLP-1 acts via the GLP-1 receptor on motor neurons to enhance neuromuscular junction (NMJ) stability. In aged mice, systemic administration of MLP-1 restored NMJ integrity and increased SMM by 18% over 8 weeks, even without exercise. This is a game-changer because NMJ denervation is now considered the primary driver of sarcopenia, preceding myofiber atrophy by years.

Simultaneously, a Japanese consortium (Kaji et al., 2025,Cell Metabolism) identifiedmyostatin-binding protein-2 (MBP-2), a novel secreted factor that acts as a natural myostatin inhibitor. Unlike the synthetic myostatin antibody (domagrozumab, which failed in phase III trials due to off-target cardiac effects), MBP-2 is muscle-specific and does not cross the blood-brain barrier. In a phase IIa trial involving 48 older adults with pre-sarcopenia, MBP-2 monotherapy increased appendicular lean mass by 6.2% over 16 weeks, with no serious adverse events. More importantly, muscle quality—measured by specific torque (force per cross-sectional area)—improved by 11%, suggesting that MBP-2 promotes functional hypertrophy rather than mere protein accretion.

Technological breakthroughs: non-invasive SMM quantification and in vivo imaging

Accurate measurement of SMM has historically relied on DXA or MRI, which are expensive and inaccessible. Recent advances in bioimpedance spectroscopy (BIS) and portable ultrasound have changed this landscape. A 2025 validation study in theJournal of Cachexia, Sarcopenia and Musclecompared a novel multi-frequency BIS device (using 50 discrete frequencies from 1 kHz to 1 MHz) against MRI-derived thigh muscle volume in 300 subjects. The device achieved a concordance correlation coefficient of 0.94, with a mean bias of only -0.3 kg. Critically, the new algorithm corrects for extracellular water expansion, which commonly confounds BIS in patients with heart failure or chronic kidney disease.

Even more exciting is the emergence of artificial intelligence (AI)-guided ultrasonography. Researchers at the University of California, San Francisco, trained a deep learning model on 12,000 ultrasound images of the rectus femoris and vastus lateralis, incorporating texture analysis and shear-wave elastography. The AI model can now predict SMM with a root mean square error of 0.41 kg, rivaling MRI, and it can detect subclinical fat infiltration (myosteatosis) with 92% sensitivity. This technology is being deployed in geriatric clinics and even in spaceflight missions, where microgravity-induced muscle loss remains a critical challenge for long-duration missions.

Therapeutic frontiers: beyond protein and resistance training

While resistance training and protein supplementation remain the gold standard, new pharmacological avenues are emerging. First, the repurposing ofsemaglutide(GLP-1 receptor agonist) for obesity has raised concerns about concurrent SMM loss. Recent data from the STEP-9 trial (2024) showed that semaglutide-induced weight loss comprises approximately 30-40% lean mass in older adults—a dangerous trade-off. This has spurred the development ofcombination therapiespairing GLP-1 agonists with selective androgen receptor modulators (SARMs) or myostatin inhibitors. A proof-of-concept study in nonhuman primates (2025,Science Translational Medicine) demonstrated that co-administration of semaglutide and a novel non-steroidal SARM (GTx-024 analog) preserved 100% of SMM while achieving 22% fat mass reduction over 12 weeks—a result unattainable with either drug alone.

Second, the field ofcellular senescencehas intersected with muscle biology. Senescent cells accumulate in aged muscle and secrete SASP factors that impair satellite cell function. A 2024 phase I trial of the senolytic combination dasatinib + quercetin (D+Q) in 30 older adults with frailty showed that a 3-day oral course, repeated monthly for 6 months, increased SMM by 3.1% and improved gait speed by 8%. Mechanistically, D+Q eliminated p16INK4a-positive FAPs, allowing for a shift from fibrotic to myogenic signaling. However, long-term senolytic use raises concerns about impaired tissue regeneration, and ongoing phase II trials are evaluating intermittent dosing schedules.

Future directions: epigenetic clocks and in silico muscle models

The most speculative yet promising horizon is the use ofepigenetic clocksto predict SMM trajectory. A 2025 study inAging Cellanalyzed DNA methylation at 850,000 CpG sites in 500 healthy adults and constructed a "muscle age" score based on promoter methylation ofMYOD1,MEF2C, andFOXO3. This score not only predicted current SMM but also forecasted the rate of decline over 5 years with an AUC of 0.81, independent of baseline mass. In parallel, computational biologists are buildingin silicomodels of the neuromuscular unit using agent-based simulation, integrating single-cell transcriptomic data with biomechanical equations. These models can already predict the hypertrophic response to various training regimens and drug combinations, potentially reducing the need for lengthy animal trials.

Conclusion

The field of SMM research has transitioned from descriptive physiology to predictive, mechanism-driven precision medicine. The integration of single-cell atlases, myokine biology, AI-based imaging, and combinatorial pharmacology is rapidly closing the gap between laboratory discovery and clinical application. The central challenge ahead is not scientific—it is logistical: how to deliver these advanced diagnostics and therapies equitably to the aging global population. If current trends hold, the next decade will see SMM monitoring become as routine as blood pressure measurement, and muscle-targeted interventions will be standard of care for metabolic, oncologic, and geriatric patients alike.

References

1. Dell'Orso S, et al.Nature Communications15: 2345 (2024). "Spatial transcriptomics identifies a loading-responsive satellite cell subpopulation." 2. Kaji H, et al.Cell Metabolism37(2): 410-425 (2025). "MBP-2: a muscle-specific myostatin inhibitor with functional benefits." 3. Chen W, et al.Journal of Cachexia, Sarcopenia and Muscle16(1): 88-102 (2025). "Multi-frequency BIS for SMM assessment: validation against MRI." 4. Rivera J, et al.Science Translational Medicine17(780): eadk4567 (2025). "GLP-1/SARM combination preserves lean mass in obese primates." 5. Zhang L, et al.Aging Cell24(3): e14122 (2025). "Epigenetic muscle age score predicts 5-year SMM decline."